Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (74)	12/4/1997 1:22:00 PM
From: Vector1	Read Replies (1) \| Respond to of 666

Stan, it all depends on the stage of development. Early stage projects ( pre clinical)usually result in single digit royalties to the developer. Early clinical is usually higher but still in the single digits depending on the cost of the trials and the up front payment. Later stage is more evenly split with in many cass the biotech keeping rights in certain jurisdictions or for certain indications. I believe IDPH gets 40% in its deal with Genentech but I will have to check. If CLTR waits until they have compelling phase III data they may have to give up as little as 15- 20%. V1